Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Over 750 industry clinical trials have been initiated for...
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and...
The imaging clinical trials industry continues to grow in the face of unique challenges! To help you keep up, we’ve put together the top trends to...
Learn how QMENTA simplifies central vein detection in Multiple Sclerosis. Our solution automates protocol adherence, sequence recognition, and white...
QMENTA's neuroimaging platform enables Parkinson's disease research through AI-powered MRI and PET biomarker analysis — including iron accumulation,...
Discover how the Central Vein Sign (CVS) — with 95% sensitivity and 92% specificity — is transforming MS diagnosis and how QMENTA powered the CAVS-MS...
Learn how to integrate AI tools into medical imaging workflows using QMENTA's cloud platform — covering benefits of AI in imaging, key challenges,...
Take a look ahead at our predicted trends for neuroscience in 2025 - where technology, neuroplasticity, and neuroethics are reshaping the way we...